
Updated Shareholder Information - Top 20 Holders & Securities Distribution

Resonance Health Limited (Resonance or Company) (ASX: RHT) provides the enclosed updated shareholder information disclosure in accordance with Australian Securities Exchange (**ASX**) Listing Rule 4.10.

The update includes information about the Company's corporate governance, the distribution of securities, the twenty largest security holders of quoted securities, substantial holders, and voting rights.

This information is current on 29 August 2025, and it replaces the shareholder information contained at the end of the Annual Report of the Company (pages 67-69) lodged on the ASX platform on 29 August 2025.

This announcement has been authorised for release in accordance with the delegated authority of the Board of Directors of Resonance Health Ltd. For further information please contact:

Mitchell Wells – Non-executive Director & Company Secretary

E: mitchellw@resonancehealth.com

P: +61 (0)8 9286 5300

About Resonance Health

Resonance Health is an Australian healthcare technology and services company. The Company's services are used globally by clinicians in the management of human diseases and by pharmaceutical and therapeutic companies in their clinical trials. Resonance Health has gained endorsement by leading physicians worldwide for providing high quality quantitative assessments essential in managing diseases and drug development.

Resonance Health's dedication to scientific rigour and quality has enabled it to achieve regulatory clearances for a range of Software-as-Medical Devices (**SaMDs**) in the USA, Europe, UK, and Australia, and to proudly carry ISO 13485 certification for the design and manufacture of medical devices. Regulatory cleared SaMD products, some of which incorporate Artificial Intelligence (**AI**), include:

- **FerriScan®**, a core-lab product that provides an accurate assessment of liver iron concentration (**LIC**) through non-invasive MRI-based technology, for use in the assessment of individuals with iron overload conditions. Internationally recognised as the gold standard in LIC assessment.
- **FerriSmart®**, an AI-trained, non-invasive MRI-based device for the automated real-time assessment of LIC in participants, calibrated against the global gold standard, FerriScan®.
- **HepaFatScan®**, an MRI-based solution which provides a reliable non-invasive assessment of liver-fat in liver tissue for use in the assessment of individuals with confirmed or suspected fatty-liver-disease.
- **HepaFatSmart®**, an AI-trained, non-invasive device for the automated real-time multi-metric assessment of liver-fat in participants, for the assessment of individuals with confirmed or suspected fatty liver disease.
- **LiverSmart®**, an AI-trained, non-invasive MRI-based multi-parametric device combining FerriSmart® and HepaFat-AI® into a consolidated report providing accurate assessment of LIC and liver fat.

- **CardiacT2***, the most widely accepted MRI method for assessing heart iron loading. Resonance Health offers a dual analysis of FerriScan® and CardiacT2*.

The Company has a development pipeline of additional medical imaging analysis products and services, including the **MRI Liver Fibrosis Project**, aimed at accurately assessing the presence and progression of liver fibrosis utilising non-invasive MRI analysis

The Company also has a clinical trials business which both manages clinical trials in Australia and includes the site management operations of TrialsWest.

Stakeholders, including clinicians, participants, and shareholders, are encouraged to register their interest at www.resonancehealth.com and to follow Resonance Health on LinkedIn.

The following additional information is disclosed in accordance with section 4.10 of the Australian Securities Exchange Listing Rules in respect of a listed public company.

The shareholder information set out below was applicable at 29 August 2025.

Corporate Governance

In recognising the need for the high standards of corporate behaviour and accountability, the Company's Directors support and adhere to corporate governance principles. The Company's Corporate Governance Statement is included with the Appendix 4G of the Company - lodged on the ASX platform on or about the time of the Company's Annual Report.

Distribution of equitable securities

Fully-paid ordinary shares (main class) by size of holding:

	Ordinary shares		
	Number of holders	Number of	% of total shares issued
1 to 1,000	120	18,155	0.00
1,001 to 5,000	171	622,483	0.13
5,001 to 10,000	181	1,448,369	0.31
10,001 to 100,000	800	34,077,636	7.24
100,001 and over	432	434,594,672	92.32
	<u>1,704</u>	<u>470,761,315</u>	<u>100.00</u>
Holding less than a marketable parcel	515	2,573,049	0.55

Substantial holders

Substantial holders in the Company are as follows:

	Ordinary shares	
	Number held	% of total shares issued
SOUTHAM INVESTMENTS 2003 PTY LTD <WARWICKSHIRE INVESTMENT A/C>	74,800,000	15.89
HSBC CUSTODY NOMINEES (AUSTRALIA) LIMITED	40,166,463	8.53

Voting rights

The voting rights attached to ordinary shares are that on a poll each share shall have one vote.

Equity security holders

Twenty largest quoted equity security holders:

The names of the twenty largest security holders of quoted equity securities are listed below:

	Ordinary shares	
	Number held	% of total shares issued
SOUTHAM INVESTMENTS 2003 PTY LTD <WARWICKSHIRE INVESTMENT A/C>	74,800,000	15.89
HSBC CUSTODY NOMINEES (AUSTRALIA) LIMITED	40,166,463	8.53
BNP PARIBAS NOMS PTY LTD	11,709,576	2.49
BEPI INVESTMENTS PTY LTD <SUN TZU A/C>	11,070,857	2.35
MR ANDREW DUNCAN HARRISON & MRS KATRINA ELLEN HARRISON <HARRISON SUPER FUND A/C>	8,000,000	1.70
MR HARISH GARG	7,900,000	1.68
BENJAMIN CARRUTHERS <CARRUTHERS FAMILY A/C>	7,342,553	1.56
MR WILLIAM MURRAY THOMPSON	6,658,660	1.41
MS JADE LOUISE THOMPSON	6,512,759	1.38
MR BRUCE ALAN STEVENSON	6,400,000	1.36
MR THOMAS PSARAKIS	5,434,777	1.15
MARCOLONGO NOMINEES PTY LTD <MARCOLONGO FAMILY A/C>	5,186,200	1.10
MR HELMUT ROCKER	5,000,000	1.06
MR EVAN GEORGE CROSS & MRS DONNA SHARON CROSS <DEC SUPERANNUATION FUND A/C>	5,000,000	1.06
DR MARTIN PETER BLAKE	3,798,590	0.81
MR PAUL ANDREW FITZMAURICE & MRS TANIA MARIE FITZMAURICE <FITZMAURICE FAMILY S/F A/C>	3,750,000	0.80
THE UNIVERSITY OF WESTERN AUSTRALIA	3,478,750	0.74
CORNUCOPIA ASSETS PTY LTD <CORNUCOPIA SUPER FUND A/C>	3,240,619	0.69
NEWECONOMY COM AU NOMINEES PTY LIMITED <900 ACCOUNT>	3,171,813	0.67
MS NEERU RANI	3,100,000	0.66
MR ANDREW FREDERICK TROWSE <A F TROWSE FAMILY A/C>	2,964,985	0.63
	<u>224,686,602</u>	<u>47.73</u>
TOTAL ISSUED CAPITAL	<u>470,761,315</u>	<u>100.00</u>